Revisiting the role of molecular targeted therapies in patients with brain metastases.
about
Evaluation of the Safety and Benefit of Phase I Oncology Trials for Patients With Primary CNS Tumors.Brain metastases: an overview.The efficacy and limitations of stereotactic radiosurgery as a salvage treatment after failed whole brain radiotherapy for brain metastases.Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors.
P2860
Revisiting the role of molecular targeted therapies in patients with brain metastases.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 July 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Revisiting the role of molecular targeted therapies in patients with brain metastases.
@en
Revisiting the role of molecular targeted therapies in patients with brain metastases.
@nl
type
label
Revisiting the role of molecular targeted therapies in patients with brain metastases.
@en
Revisiting the role of molecular targeted therapies in patients with brain metastases.
@nl
prefLabel
Revisiting the role of molecular targeted therapies in patients with brain metastases.
@en
Revisiting the role of molecular targeted therapies in patients with brain metastases.
@nl
P2860
P1476
Revisiting the role of molecular targeted therapies in patients with brain metastases
@en
P2093
Dionysis Papadatos-Pastos
P2860
P2888
P304
P356
10.1007/S11060-011-0661-Y
P50
P577
2011-07-22T00:00:00Z